Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 8Lymphoid 7Other hematologic neoplasm 5Myeloid 2Dermatologic 2Breast 1

Conditions

Melanoma 2Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Blood Component Removal × Dermatologic × Clear all
NCT03325101 2025-06-12

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

Mayo Clinic

Phase 1/2 Terminated
7 enrolled 11 charts
Dermatologic

Melanoma

NCT00001832 2012-12-21

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
170 enrolled 23 charts
BreastDermatologic

Breast Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡